Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LENZ Therapeutics, Inc.GRPH · Entity 6475 | Director | July 19, 2023 | July 21, 2023 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | December 29, 2022 | January 03, 2023 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Director | August 08, 2025 | August 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LENZ Therapeutics, Inc.
Report date July 19, 2023 · Filed July 21, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.72 · Expires 2033-07-18 | Direct | 20,000 |
Reported balance
After 2023-07-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-19 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to such option vest in full on the earlier of (i) the one-year anniversary of the grant date or on (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
Repare Therapeutics Inc.
Report date December 29, 2022 · Filed January 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 563,403 |
Reported balance
After 2022-12-29 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2022-12-29 · Other · Disposed 287,157 · Balance 563,403 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners. F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 62,026 |
Reported balance
After 2022-12-29 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2022-12-29 · Other · Acquired 62,026 · Balance 62,026 F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 16,949 |
Reported balance
After 2022-12-29 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2022-12-29 · Other · Disposed 8,638 · Balance 16,949 F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners. F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 63,892 |
Reported balance
After 2022-12-29 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2022-12-29 · Other · Acquired 1,866 · Balance 63,892 F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 18,761 |
Reported balance
After 2022-12-29 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2022-12-29 · Other · Disposed 9,561 · Balance 18,761 F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners. F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 65,957 |
Reported balance
After 2022-12-29 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2022-12-29 · Other · Acquired 2,065 · Balance 65,957 F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-12-29 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2022-12-29 · Other · Disposed 65,957 · Balance 0 F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 42,877 |
Reported balance
After 2022-12-29 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2022-12-29 · Other · Disposed 21,854 · Balance 42,877 F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners. F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 4,721 |
Reported balance
After 2022-12-29 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2022-12-29 · Other · Acquired 4,721 · Balance 4,721 F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2022-12-29 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2022-12-29 · Other · Disposed 4,721 · Balance 0 F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 2,094,451 |
Reported balance
Holding disclosure · report date 2022-12-29 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 2,094,451 F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | IndirectSee Footnote | 231,211 |
Reported balance
Holding disclosure · report date 2022-12-29 · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · Balance 231,211 F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein. |
| Common SharesSEC Table I · non-derivative | Direct | 25,131 |
Ending reported balance
After 2022-12-29 transaction · row 12
2 source rows · reconciled sequenceRow 8 · 2022-12-29 · Other · Acquired 1,240 · Balance 22,117 F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V. Row 12 · 2022-12-29 · Other · Acquired 3,014 · Balance 25,131 F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V") to its partners.
F2: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein.
F3: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V.
F4: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, the Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F5: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V") to its partners.
F6: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein.
F7: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V.
F8: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I") to its partners.
F9: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein.
F10: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I.
F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members.
F12: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V.
F13: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)") to its partners.
F14: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein.
F15: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada).
F16: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein.
F17: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners.
F18: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V (Canada).
F19: Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and the Reporting Person disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interests therein.
F20: Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. The Reporting Person, a member of the Issuer's board of directors, is a managing director of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and the Reporting Person disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interests therein.
Turnstone Biologics Corp.
Report date August 08, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Versant Vantage II, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-08-08 · Other · Disposed 274,990 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-08-08 · Other · Disposed 2,726,322 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Venture Capital V (Canada) LP | 0 |
Reported balance
After 2025-08-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-08-08 · Other · Disposed 207,486 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Ophthalmic Affiliates Fund I, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-08-08 · Other · Disposed 90,888 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Versant Affiliates Fund V, L.P. | 0 |
Reported balance
After 2025-08-08 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2025-08-08 · Other · Disposed 82,006 · Balance 0 F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest. F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the terms of the Agreement and Plan of Merger, dated June 26, 2025, by and among the Issuer, XOMA Royalty Corporation ("Purchaser") and XRA 3 Corp., a wholly-owned subsidiary of Purchaser, pursuant to which Purchaser completed a cash tender offer for all outstanding shares of common stock of the Issuer for (i) $0.34 per share in cash, payable subject to any applicable tax withholding and without interest, plus (ii) one non-transferable contractual contingent value right per share, payable subject to any applicable tax withholding and without interest.
F2: Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
F3: Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.
F4: Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
F5: Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.
F6: Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CHINOOK THERAPEUTICS, INC.
Report date August 11, 2023 · Filed August 11, 2023
Section 16 reporting ended · disclosed 2023-08-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 1
1 source rowRow 1 · 2023-08-11 · Disposition to issuer · Disposed 447,013 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2023-08-11 · Disposition to issuer · Disposed 2,105,107 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2023-08-11 · Disposition to issuer · Disposed 719,104 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2023-08-11 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-08-11 · Disposition to issuer · Disposed 210,996 · Balance 0 F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger. F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.77 · Expires 2030-10-05 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-08-11 · Disposition to issuer · Disposed 23,522 · Balance 0 F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.81 · Expires 2031-06-03 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-08-11 · Disposition to issuer · Disposed 5,948 · Balance 0 F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.88 · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2023-08-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-08-11 · Disposition to issuer · Disposed 13,300 · Balance 0 F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the Merger Agreement (defined in the Remarks below). Upon effectiveness of the Merger (defined in the Remarks below), in exchange for each share of the Issuer's Common Stock, the reporting person received: (i) $40.00 in cash, without interest and less applicable withholding taxes; and (ii) one contractual contingent value right (each, a "CVR"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement (the "Contingent Value Rights Agreement") entered into concurrent with completion of the Merger.
F2: These securities are held of record by Versant Venture Capital VII, L.P. ("Versant VII"). Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII. Each of Jerel C. Davis, Versant Ventures VII GP-GP, and Versant Ventures VII GP disclaims beneficial ownership of the shares held by Versant VII, except to the extent of their respective pecuniary interests therein.
F3: These securities are held of record by Versant Voyageurs I, L.P. ("Versant Voyageurs I"). Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel C. Davis is a member of the Issuer's board of directors and is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I. Each of Jerel C. Davis and Versant Voyageurs I GP Company disclaims beneficial ownership of the shares held by Versant Voyageurs I, except to the extent of their respective pecuniary interests therein.
F4: These securities are held of record by Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"). Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant Voyageurs I GP. Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Jerel C. Davis is a member of the Issuer's board of directors and is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel. Each of Jerel C. Davis, Versant Ventures VI GP-GP, Versant Ventures VI GP, and Versant Voyageurs I GP disclaims beneficial ownership of the shares held by Versant I Parallel, except to the extent of their respective pecuniary interests therein.
F5: This stock option award, which provided for ratable vesting in 36 monthly installments beginning on November 6, 2020, became fully vested and was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
F6: This stock option award, which vested in full upon the earlier of the one year anniversary of the grant date or the date of the Issuer's next annual stockholders' meeting, was canceled upon effectiveness of the Merger, and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one CVR, entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the Contingent Value Rights Agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,388 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 11 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F17 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V (Canada), to its partners. F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,388 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 10 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,388 F15 · kind: Represents a change in the form of ownership of VV V (Canada) by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V (Canada). F16 · ownership.nature: Shares held by VV V (Canada). VV V (Canada) GP is the sole general partner of VV V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VV V (Canada). Each of VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VV V (Canada), except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 11,688 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 9 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 180,995 F13 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"), to its partners, pursuant to a Rule 10b5-1 trading plan. F14 · ownership.nature: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,062 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 8 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,062 F12 · kind: Represents a change in the form of ownership of the Reporting Person by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VV V. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 35,276 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 7 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F11 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by VV V, to its members. F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 1,105 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 6 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 35,276 F10 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VOAF I. F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 5,113 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 5 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 79,188 F8 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F9 · ownership.nature: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 998 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 34,171 F7 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VAF V. F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 4,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 71,538 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F6 · ownership.nature: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 33,173 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 33,173 F3 · kind: Represents a change in the form of ownership of VV V by virtue of the receipt of shares in the pro-rata in-kind distribution of common shares of the Issuer for no consideration by VVC V. F4 · ownership.nature: Shares held by VV V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VV V; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| January 14, 2021 Filed Jan 20, 2021 00:40 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 153,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-002397 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,378,225 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interests therein. The Reporting Person is a director of the Issuer and, accordingly files separate Section 16 reports. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 21,707 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034364 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 192,683 F7 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"), to its partners, pursuant to a Rule 10b5-1 trading plan. F8 · ownership.nature: Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). The Reporting Person, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and the Reporting Person disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 9,497 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034364 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,301 F5 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates, L.P. ("VOAF I"), to its partners, pursuant to a Rule 10b5-1 trading plan. F6 · ownership.nature: Shares held by VOAF I. VV V is the sole general partner of VOAF I. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 8,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034364 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 76,158 F3 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F4 · ownership.nature: Shares held by VAF V. VV V is the sole general partner of VAF V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interest therein. Read SEC document |
| December 15, 2020 Filed Dec 18, 2020 02:04 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | OtherCommon Shares | 285,217 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-034364 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,531,804 F1 · kind: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V"), to its partners, pursuant to a Rule 10b5-1 trading plan. F2 · ownership.nature: Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. The Reporting Person, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and the Reporting Person disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interest therein. Read SEC document |
| October 06, 2020 Filed Oct 7, 2020 21:02 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantStock Option (right to buy) · Derivative | 23,522 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-20-054248 · doc4.xml · derivative · entry 5 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,522 Underlying: Common Stock · 23,522 shares Expires 2030-10-05 F6 · derivative.exercise_date: The stock option vests as of 1/36 of the total shares monthly beginning on November 6, 2020 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:02 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantCommon Stock | 2,433,099 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054248 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,433,099 F2 · shares: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F1 · price: The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer. F2 · ownership.nature: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F5 · ownership.nature: These securities are held of record by Versant Voyageurs I. Versant Voyageurs I GP Company is the general partner of Versant Voyageurs I. Jerel Davis is a director of Versant Voyageurs I GP Company and may be deemed to share voting and dispositive power over the shares held by Versant Voyageurs I; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:02 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantCommon Stock | 722,247 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054248 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 722,247 F2 · shares: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F1 · price: The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer. F2 · ownership.nature: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F4 · ownership.nature: These securities are held of record by Versant I Parallel. Versant Voyageurs I GP, L.P. ("Versant Voyageurs I GP") is the general partner of Versant I Parallel. Versant Ventures VI GP, L.P. ("Versant Ventures VI GP-GP") is the general partner of Versant Voyageurs I GP LP. Versant Ventures VI GP-GP is the general partner of Versant Ventures VI GP. Jerel Davis is a managing director of Versant Ventures VI GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant I Parallel; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:02 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantCommon Stock | 4,733,023 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054248 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,733,023 F2 · shares: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F1 · price: The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer. F2 · ownership.nature: The Reporting Person is a managing director or a director of the ultimate general partner or general partner of Versant Venture Capital VII, L.P. ("Versant VII"), Versant Voyageurs I Parallel, L.P. ("Versant I Parallel"), and Versant Voyageurs I, L.P. ("Versant Voyageurs I"). This report shall not be deemed an admission that any of the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. F3 · ownership.nature: These securities are held of record by Versant VII. Versant Ventures VII GP, L.P. ("Versant Ventures VII GP") is the general partner of Versant VII, and Versant Ventures VII GP-GP, LLC ("Versant Ventures VII GP-GP") is the general partner of Versant Ventures VII GP. Jerel Davis is a managing director of Versant Ventures VII GP-GP and may be deemed to share voting and dispositive power over the shares held by Versant VII; however, he disclaims beneficial ownership of such securities, except to the extent of his pecuniary interests therein. Jerel Davis is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 21:02 UTC | CHINOOK THERAPEUTICS, INC. KDNY · Entity 110632 | GrantCommon Stock | 730,470 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054248 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 730,470 F1 · price: The shares reported represent the number of shares of Issuer common stock received by the Reporting Person on the Effective Date in connection with merger of Chinook Therapeutics U.S., Inc. ("Private Chinook") into the Issuer. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 458,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 24 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 458,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F7 · ownership.nature: The securities are held by Versant Vantage I, L.P. ("VV I"). The Reporting Person is a managing member of the ultimate general partner of VV I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 875,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 23 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 875,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F6 · ownership.nature: The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 22 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 3,350 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F5 · ownership.nature: The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). The Reporting Person is a managing member of the general partner of VAF V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 3,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 21 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 3,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). The Reporting Person is a managing member of the general partner of VOAF I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 8,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 20 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 8,475 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). The Reporting Person is a director of the ultimate general partner of VVC V (Canada), but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass B Preferred Shares · Derivative | 111,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 19 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 111,361 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held by Versant Venture Capital V, L.P. ("VVC V"). The Reporting Person is a managing member of the general partner of VVC V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass A Preferred Shares · Derivative | 2,443,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 18 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 2,443,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F6 · ownership.nature: The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass A Preferred Shares · Derivative | 61,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 17 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 61,791 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F5 · ownership.nature: The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). The Reporting Person is a managing member of the general partner of VAF V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass A Preferred Shares · Derivative | 68,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 16 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 68,398 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). The Reporting Person is a managing member of the general partner of VOAF I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass A Preferred Shares · Derivative | 156,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 15 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 156,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). The Reporting Person is a director of the ultimate general partner of VVC V (Canada), but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionClass A Preferred Shares · Derivative | 2,054,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · derivative · entry 14 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Shares · 2,054,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held by Versant Venture Capital V, L.P. ("VVC V"). The Reporting Person is a managing member of the general partner of VVC V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | PurchaseCommon Shares | 100,000 | $20.00 | $2,000,000.00 |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 13 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,419,451 F6 · ownership.nature: The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. F9 · ownership.nature: These securities were purchased by VVC VI. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | PurchaseCommon Shares | 150,000 | $20.00 | $3,000,000.00 |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 12 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 608,282 F7 · ownership.nature: The securities are held by Versant Vantage I, L.P. ("VV I"). The Reporting Person is a managing member of the ultimate general partner of VV I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. F8 · ownership.nature: These securities were purchased by VV I. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 458,282 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 11 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 458,282 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F7 · ownership.nature: The securities are held by Versant Vantage I, L.P. ("VV I"). The Reporting Person is a managing member of the ultimate general partner of VV I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 875,568 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 10 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,319,451 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F6 · ownership.nature: The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 3,350 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 9 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 84,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F5 · ownership.nature: The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). The Reporting Person is a managing member of the general partner of VAF V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 3,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 8 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 93,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). The Reporting Person is a managing member of the general partner of VOAF I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 8,475 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 7 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 214,390 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). The Reporting Person is a director of the ultimate general partner of VVC V (Canada), but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 111,361 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 6 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,817,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held by Versant Venture Capital V, L.P. ("VVC V"). The Reporting Person is a managing member of the general partner of VVC V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 2,443,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 5 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,443,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F6 · ownership.nature: The securities are held by Versant Venture Capital VI, L.P. ("VVC VI"). The Reporting Person is a managing member of the ultimate general partner of VVC VI, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 61,791 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 4 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 81,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F5 · ownership.nature: The securities are held by Versant Affiliates Fund V, L.P. ("VAF V"). The Reporting Person is a managing member of the general partner of VAF V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 68,398 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 3 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 90,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F4 · ownership.nature: The securities are held by Versant Ophthalmic Affiliates Fund I, L.P. ("VOAF I"). The Reporting Person is a managing member of the general partner of VOAF I, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 156,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 2 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 205,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F3 · ownership.nature: The securities are held by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"). The Reporting Person is a director of the ultimate general partner of VVC V (Canada), but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 23:09 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | ConversionCommon Shares | 2,054,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-038999 · doc4.xml · nonDerivative · entry 1 Jerel Davis · CIK 0001745958 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,705,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: Each Class A Preferred Share and each Class B Preferred Share converted into the same number of Common Shares upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The securities are held by Versant Venture Capital V, L.P. ("VVC V"). The Reporting Person is a managing member of the general partner of VVC V, but disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.